One of the critical roles philanthropic investment can play is in supporting science that might not be readily fundable elsewhere. What are the most exciting new developments in medical science that might actually have a significant impact on patients in the next five years? How are the boundaries between disease areas becoming blurred, and what are the implications for how we conduct research? Do we have the resources - financial, human, and information - needed to support this kind of breakthrough science?

Moderator:
James Greenwood, President and Chief Executive Officer, Biotechnology Industry Organization

Speakers:
Mara Aspinall, President and Chief Executive Officer, On-Q-ity
Stephen Friend, President, CEO and Co-Founder, Sage Bionetworks Mara Aspinall, On-Q-ity
Levi Garraway, M.D., Ph.D., Department of Medical Oncology, Dana-Farber Cancer Institute and Associate Physician, Brigham and Women’s Hospital
Garry Neil, Corporate Vice President, Corporate Office of Science and Technology, Johnson & Johnson
Rudy Tanzi, Professor of Neurology, Massachusetts General Hospital